MedTrace Logo

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

NCT07272837 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-04-20

No results posted yet for this study

Summary

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

This study involves (3) in-person study visits. At each visit, participants will be asked to:

* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
* Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
* Complete questionnaires related to demographics, health information, physical activity, and nutrition.
* Have a blood sample collected from a vein in your arm.
* Have your blood levels assessed through three finger pricks.
* Complete three days of food records.

Conditions

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-14
Primary Completion
2027-12-31
Completion
2028-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07272837 on ClinicalTrials.gov